A phase i study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer

Kari B. Wisinski, Wendy M. Ledesma, Jill Kolesar, George Wilding, Glenn Liu, Jeffrey Douglas, Anne M. Traynor, Mark Albertini, Daniel Mulkerin, Howard H. Bailey

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'A phase i study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science